PDAC biomarker identification and validation. Biomarkers in ex vivo expanded CTCs will be recognized by stringent statistical analysis and subjected to further characterization in three studies. First, we will confirm the association of biomarkers with CTCs and CTC-PDX models. Second, the biomarkers will be validated for correlation with clinical PDAC metastasis and therapeutic resistance. Finally, we will retrospectively test the application of selected biomarkers in PDAC diagnosis, treatment evaluation and disease prognosis. As biomarkers could be in the form of genomic abnormalities or transcriptional aberrations, corresponding methods will be used for validation, which we have previously reported (118-120). The ultimate objective is to develop biomarker detection protocols for cost-effective and non-invasive detection of clinical PDAC in a highly sensitive and specific fashion.
Genomic PCR will be tested extensively as a convenient and preferred tool for detecting biomarkers of genomic abnormalities. After confirmation on ex vivo expanded CTCs, optimal PCR settings will be established and tested for detection of CTCs directly from blood samples, first from the blood of mice …show more content…
The aCGH assay will be an essential tool to assess the genomic changes. Based on the results of SKY and aCGH analyses, representative CTC cultures will be subjected to mutation screening in CTC, CTD-PDX and biopsy materials by whole genome sequencing using NGS for comprehensive molecular profiling of abnormalities at the nucleotide level. NGS data will be transferred to Palanisamy, who will carry out biostatistics and bioinformatics analysis. Given the unbiased nature of NGS analysis, we anticipate identifying new druggable genomic mutations on a personalized
Genomic PCR will be tested extensively as a convenient and preferred tool for detecting biomarkers of genomic abnormalities. After confirmation on ex vivo expanded CTCs, optimal PCR settings will be established and tested for detection of CTCs directly from blood samples, first from the blood of mice …show more content…
The aCGH assay will be an essential tool to assess the genomic changes. Based on the results of SKY and aCGH analyses, representative CTC cultures will be subjected to mutation screening in CTC, CTD-PDX and biopsy materials by whole genome sequencing using NGS for comprehensive molecular profiling of abnormalities at the nucleotide level. NGS data will be transferred to Palanisamy, who will carry out biostatistics and bioinformatics analysis. Given the unbiased nature of NGS analysis, we anticipate identifying new druggable genomic mutations on a personalized